Farmacogenetics and adverse reaction to drugs
Predictive value of polymorphism in the uridine diphosphate glucoronosyltransferase 1A1 gene
Keywords:
ANTINEOPLASTIC AGENTS, IRINOTECAN, GLUCURONOSYLTRANSFERASE, GENETIC VARIATIONAbstract
Introduction: adverse reactions to drugs constitute an essential problem for health services, the pharmaceutical industry and the regulatory bodies. Most of these reactions are relatively mild and they disappear when dosage is modified, although others are more serious and they may result in death. Irinotecan is an active cytotoxic agent in colorectal and lung cancer. It is associated to severe hematological and gastrointestinal toxicity, unpredictable in practice. Its active metabolite (SN-38) is detoxified by the uridine diphosphate glucoronosyltransferase 1A1enzyme (UGT1A1). (UGT1A1). Variation in the activity of this enzyme has been associated to polymorphisms in the UGT1A1 gene, what results in the adverse reactions observed. The most important polymorphisms appear in the polymorphism of the promoting region, which consists in a variable repetition of thymine-adenine repetitions. The main allele has six repetitions (TA)6, being the seven repetition polymorphism the most frequent allelic variant.
Objetive: to design a molecular test to study allelic variants of the promoting region in the UGT1A1 gene.
Method: We selected a group of 50 volunteers with no family bonds. Amplification and subsequent sequencing of the promoting region were used to determine molecules.
Results: we managed to update the suggested molecular diagnosis and determined that 8% of this population is a homozygote (TA)7. We propose the advantage of incorporating the results of this molecular test for the making of therapeutic decisions and thus make progress toward a more personalized oncologic medicine.
References
(2) Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anti-Cancer Drugs 2007; 18(2): 111-26.
(3) Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62(3): 608-17.
(4) Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42(7): 1007-17.
(5) Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21(5): 807-14.
(6) Gupta E, Lestingi TM, Mick R, Ramírez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54(14): 3723-5.
(7) Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60(24): 6921-6.
(8) Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995; 333(18): 1171-5.
(9) Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95(14): 8170-4.
(10) Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43-7.
(11) Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22(8): 1382-8.
(12) Fang JL, Lazarus P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 2004; 13(1): 102-9.
(13) Ratain MJ, Di Rienzo A, Iyer L, inventors. Methods for detection of promoter polymorphism in a UGT gene promoter. Origin: AUSTIN, TX US. IPC8 Class: AA61K31435FI. USPC Class: 514283. Patent application number: 2009031 8487.
(14) Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21(1): 41-6.
(15) Innocenti F, Grimsley C, Das S, Ramírez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12(9): 725-33.
(16) Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13(11): 3269-75.
